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Objective: To evaluatewhether rituximab at a low dose of 250mg/m2× 2may be as effective as at higher dosages,
most commonly 375 mg/m2 × 4, used in previous studies on the treatment of patients with refractory mixed
cryoglobulinemia (MC) vasculitis associated with hepatitis C virus (HCV) infection.
Methods: We conducted a phase 2, single-arm two-stage trial (EUDRACT n. 2008-000086-38) of low-dose
rituximab in 52 patients with HCV-associated MC who were ineligible/intolerant or non-responder to antiviral
therapy. The primary outcomes were response of vasculitis evaluated by the Birmingham Vasculitis Activity
Score (BVAS) at months 3, 6 and 12, rate of relapses and time to relapse, and rate of adverse events. Our data
were comparedwith those reported in 19 published studies selected among 291 reviewed in a literature search.
Results: The cumulative response rate (complete and partial) at month 3was 81% in our patients, and 86% in 208
patients from studies using high-dose rituximab. The relapse rate andmedian time to relapse were, respectively,
41% and 6 months in our study, and 32% and 7 months in high-dose studies. Treatment-related adverse events
were 11.5% in our study and 19.9% in high-dose studies. None of these differences was statistically significant.
Conclusion: Rituximab at a low dosage of 250 mg/m2 × 2 is as effective as at higher dosages for treating MC
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Type II mixed cryoglobulinemia (MC) is a systemic vasculitis caused
by immune complexes formed by monoclonal IgM rheumatoid factor
and polyclonal IgG, which precipitate at t° less than 37° and cause
small vessel vasculitis [1]. It is currently considered a rare disease,
although the prevalence of the vasculitis presents geographical differ-
ences, in relation to HCV infection prevalence [2]. Indeed in more than
90% of cases MC is secondary to hepatitis C virus (HCV) infection,
which determines chronic stimulation and benign monoclonal expan-
sion of B-cells producing a natural poly (auto)-reactive IgM antibody.
These B cells proliferate very poorly [3], and this may explain why
immunosuppressive and cytotoxic drugs are scarcely effective in MC.
Over time, chronic stimulation of B-cells by HCVmay give rise to genetic
changes and evolution to overt lymphoma, typically splenic marginal
zone lymphoma (SMZL) [4], that may regress after eradication of HCV
with antiviral therapy [5,6].
The most frequent manifestations of MC are cutaneous leuco-
cytoclastic vasculitis leading to purpura and skin ulceration, peripheral
neuropathy, glomerulonephritis [1] and central nervous system vascu-
lar lesions thatmay underlie cognitive impairment [7]. In somepatients,
MC has an acute onset and presents a life-threatening course with skin
ulcers, renal involvement and abdominal vasculitis [8].
HCV clearance with sustained virological response (SVR) is themain
goal in the treatment of patients with HCV-associated MC, and leads
to remission of vasculitis and reduced mortality [8,9]. So far, the best
combination for achieving HCV eradication in MC patients is with
pegylated interferon alpha (PEG-IFN) and ribavirin [9]. Unfortunately,
many patients are ineligible/intolerant, fail to respond or relapse after
initial response to this regimen; these patientsmay have a grim progno-
sis and bear high health care costs [10].
New direct-acting antiviral (DAA) agents yielding 90–100% SVR
rates [11] may change this scenario, and clinical trials with IFN-free
regimens for HCV-associated cryoglobulinemia are eagerly awaited
[12].
Starting 15 years ago, a number of studies (open studies and case
reports) have demonstrated that the anti-CD20 chimeric monoclonal
antibody rituximab is highly effective for the treatment of HCV-
associated MC, refractory or intolerant to antiviral therapy [13–31].
Only recently, two randomized controlled trials [29,30] showed that
rituximab is largely superior to conventional immunosuppressive
drugs for treating cryoglobulinemic vasculitis, providing further evi-
dence of its clinical efficacy and safety in this setting. The rituximab
dosage used in nearly all published reports was 375 mg/m2 given four
times, the treatment schedule used for B cell NHL [13,14,16–20,22–28,
30]. Other studies used the dosage of 1000 mg for two administrations,
as for the treatment of rheumatoid arthritis [22,27,29,31] and only few
patients were treated with the higher dosage of 375 mg/m2 for four ad-
ministrations plus two monthly maintenance dosages [15,18,21,27].
However, the issue of optimal dosing of rituximab for treating MC has
not been addressed so far.
Low-dose regimens of rituximab have been shown to be efficacious in
different immunological disorders such as rheumatoid arthritis [32–34],
systemic lupus erythematosus [35,36], autoimmune haemolytic anemia
[37], immune thrombocytopenia [38], pemphigus [39] and myastheniagravis [40]. Remarkably, a recent meta-analysis [41] demonstrated that
low-dose rituximab (500 mg × 2) has similar effectiveness and meets
non-inferiority criteria compared to the licensed dose of 1000 mg × 2
for the treatment of rheumatoid arthritis.
Based on a pilot study in 6 patients [42], we designed a phase II,
single-arm two-stage multicenter study to evaluate the efficacy of
low-dose rituximab (250 mg/m2 given twice one week apart) in
patients with refractory HCV-associated mixed cryoglobulinemia. The
mid-term results in 27 of the 52 patients to be enrolled in this study
were published in 2011 [43]. Here we report the final results of the
study, providing confirmatory evidence of equal efficacy of low-dose
compared to high-dose rituximab for the treatment of patients with




This phase 2, single-arm, two-stage multicenter study (EUDRACT n.
2008-000086-38), aimed at assessing the efficacy/safety profile of low-
dose rituximab for refractory mixed cryoglobulinemia, was conducted
in three university centers (Sapienza University of Rome, University of
Florence and University of Pavia). The study was approved by the Inter-
nal Review Boards of all participating institutions, andwritten informed
consent was obtained from each patient according to the ethical guide-
lines of the Declaration of Helsinki.
2.2. Sample size determination and stopping rules
Sample size estimatewas performed using the Simon's optimal two-
stage procedure. Based on prior data [43], the estimated percentage of
patients reaching a 50% reduction of the Birmingham Vasculitis Activity
Score (BVAS) and of cryocrit was 40–60% after 10–12 weeks of
treatment (primary objective). Fifty-two patients were planned to be
treated; for N27/52 responders the conclusion would be that the inves-
tigational therapy is effective in these patients. The procedure described
above tests the null hypothesis (Ho) that the true response rate is 60%
versus the alternative hypothesis (Ha) that the true response rate is at
least 40%. The level of significance (i.e., the probability of rejecting the
Ho when it is true) is 0.03; the power (i.e., the probability of rejecting
the Ha when it is true) is 0.85.
Interim analysis of the results, made by the IDSMB, involved 16
patients entered into the first stage of the study. For b5/16 patients
responding to investigational therapy at week 12, the study would be
stopped on the basis of the assumption that the drug is not active
in this subset of patients. Supplementary Table 1 summarizes the
characteristics of the study design.
2.3. Patients
Fifty-two consecutive, unselected patients were enrolled in the
study. Requirements for enrolment were: diagnosis of mixed cryo-
globulinemia (type II or III) evidenced by at least one of the following
manifestations: purpura, skin ulcers, peripheral neuropathy, renal,
891M. Visentini et al. / Autoimmunity Reviews 14 (2015) 889–896gastrointestinal, pulmonary or CNS involvement, or signs and symp-
toms of hyperviscosity; chronic HCV infection, with positive serology
and/orHCV viremia. All patients had failed to respond to or had relapsed
without indication to retreatment after standard-of-care anti-HCV ther-
apywith Peg-IFNα plus ribavirin, or had contraindication or intolerance
to treatment. Patients previously treatedwith rituximabwere excluded.
Other exclusion criteria were an age below eighteen, coexistence of life-
threatening condition(s) unrelated to MC, HIV infection, a diagnosis of
hematological or non-hematological malignancy (excluding low-grade
B-cell NHL), pregnancy or breast feeding, ongoing therapy with high
dose corticosteroids and/or immunosuppressive drugs or plasmaphere-
sis, and any ongoing infection. Patients were eligible after a 2-month
washout from immunosuppressive therapy or plasmapheresis or after
healing of infection(s). Low-dose steroids were permitted through the
study. Patients with chronic hepatitis B infection were considered
ineligible, whereas patients potentially at risk for reactivation of occult
HBV (e.g., anti-HBc positive with negative anti-HBsAb, HBV viremia
and HBsAg) were considered eligible but were treated with 1-year
lamivudine prophylaxis.
Patients were treated with rituximab 250 mg/m2, given twice
at one-week interval after premedication with methylprednisolone
0.5–1 mg/kg, paracetamol 1 g and chlorpheniramine 10 mg.Table 1
Baseline demographic and clinical characteristics of the 52 study patients.
Variablea Value
Female sex, n of patients (%) 40 (77%)2.4. Efficacy assessment
Clinical and laboratory data were evaluated monthly for 12 months
after treatment; the response rates were analyzed at months 3, 6, and
12. Clinical response to treatment was defined as follows: complete
response (CR) for BVAS = 0, and partial response (PR) for BVAS b 50%
of the baseline. Primary endpoint of the study was the overall number
of patients achieving a clinical response (complete or partial) at any
time during the study. Laboratory response was defined as complete
for disappearance of cryoglobulins, and partial for a decrease of cryocrit
to less than 50% of baseline level.
Clinical relapse was defined as any increase in the BVAS score after
response, and laboratory relapse as any increase in the cryocrit level
after disappearance or significant reduction. When patients were con-
sidered non-responders or relapsers and required alternative therapies
follow-up was stopped.
Adverse events were defined as certainly or possibly related to
rituximab based on the following criteria: a) interval of time between
drug administration and event; b) disappearance of the event after
drug infusion interruption; and c) specific adverse events clearly
known as dependent on rituximab.
Severe adverse events were considered as grade 4 and grade 5, ac-
cording to the DAIDS Adverse Event Severity Grading tables (Division
of AIDS, Table for Grading the Severity of Adult and Pediatric Adverse
Events, Version 1.0, December 2004; Clarification August 2009 (online
at http://rsc.tech-res.com)).Disease duration (months), median (IQR) 48 (16–108)
Age (years), mean (±SD) 69 (±8.4)
BVAS value, mean (±SD) 13 (±6.4)
Manifestations of vasculitis, n of patients (%)
Purpura 45 (87%)




Cirrhosis, n of patients (%) 15 (29%)
Cryocrit (percent), median (IQR) 5 (3–9)
HCV load (log10 copies/ml), mean (±SD) 5.32 (±2.2)




ALT (IU/ml), median (IQR) 32 (16–57.6)
B cell count (cells/μl), median (IQR) 138 (86–255)
a IQR: interquartile range; SD: standard deviation; ALT: alanine aminotransferase.2.5. Laboratory data
All blood sampleswere drawnwith pre-warmed syringes and tubes,
allowed to clot and centrifuged at 37 °C for serum separation, according
to previously published recommendations [44]. Sera were kept at 4 °C
for 7 days and cryocrit was expressed as the percentage of serum
volume after centrifugation. The number of circulating B-cells was
measured by four-color flow cytometry in fresh blood samples using
antibodies to CD19, CD20, kappa- and lambda-chain fluorochrome-
conjugated antibodies (Becton Dickinson). B cell depletion was defined
as a value of circulating B cells ≤ 5/μl. SerumHCV RNAwasmeasured by
the Amplicor HCV assay (Roche Diagnostics). Blood samples were proc-
essed at rigorously controlled temperature, as previously described [45],
to avoid the co-precipitation of virions with cryoglobulins.2.6. Systematic review of the literature
A systematic search of the medical literature was performed in the
last week of November 2014. The search was constructed and per-
formed by an experienced librarian using Pubmed, Embase and Web
of Science. The following search strategy was used: (cryoglobulinemia
OR “cryoglobulinemic vasculitis”) AND (rituximab OR anti-CD20).
There were language restrictions (English, French, Spanish, Italian).
We retrieved 423 references, from which 126 duplicates were
eliminated and the remaining 297 records were screened; 31 studies
were retrieved as full-text, and 19 were selected for qualitative analysis
[13–31]. No quantitative comparison was possible since 17 of these 19
studies were single-arm and only two [29,30] were randomized
controlled trials; however cumulative prevalence of responders was
evaluated.
2.7. Statistical analysis
Categorical variables are expressed as count and percentages,
quantitative ones as mean and standard deviation (sd) or median and
interquartile range (IQR), as appropriate.
Categorical variables were compared with Fisher's exact test.
Analysis of variance for repeated measures models were fitted to
evaluate changes in BVAS over time, also taking into account cryocrit
as a covariate; univariate logistic regression models with outcome of
therapy as response variable were fitted to evaluate the effect of single
demographic, clinical or laboratory variables at baseline on clinical or
laboratory response. Univariate Cox regression models were fitted
with sex, age, disease duration, specific vasculitis manifestations, BVAS
value, cryocrit, HCV viremia, B-cell count or occurrence of adverse
events as independent variables and presence of relapse as response
variable.
Cumulative prevalence of responders to high dose treatment is cal-
culated across selected studies and presented with binomial exact 95%
confidence interval. Time to relapse is shown by a Kaplan–Meier curve




The characteristics of the study population are illustrated in Table 1.
All patients had at least one of the following manifestations: purpura,
Fig. 1.Kaplan–Meier curve of the duration of remission in patients responding to low-dose
(n = 41, solid line) or high-dose (n = 84, dotted line) rituximab.
892 M. Visentini et al. / Autoimmunity Reviews 14 (2015) 889–896peripheral neuropathy, skin ulcers or kidney disease. Both mild/
moderate and severe forms of cryoglobulinemic vasculitis, e.g., neurop-
athy and/or purpura vs severe skin ulcers and kidney disease [10], were
represented in the study cohort. All patients had anti-HCV antibodies,
but in 4 cases serum HCV RNA was repeatedly undetectable.
3.2. Efficacy of low-dose rituximab
3.2.1. Clinical efficacy
Supplementary Fig. 1 denotes patients' disposition through the
study. Fifty-two patients were accrued, and efficacy assessment was
done at months 3, 6 and 12. Four patients were not evaluable because
they did not reach the month 3 endpoint; one had a severe adverse
event precluding treatment, one died ofmyocardial infarction unrelated
to treatment, and two were lost to follow-up. Nine patients failed
to reach month 12; four of them died and five were lost to follow-up.
An additional patient died while in remission at month 12, and was
therefore recorded as in remission at that time point.
The primary endpoint of the study was the number of patients
achieving at any time after treatment a complete (BVAS=0) or a partial
(reduction of BVAS of at least 50% of baseline) clinical response. Thirty-
nine of 48 (81%) evaluable patients achieved a clinical response at
month 3 (Table 2), and two responded after month 3 bringing the
overall response rate to 85%; no responses aftermonth 6were recorded.
At month 12, 17 patients remained in remission whereas 17 had re-
lapsed (Supplementary Fig. 1).
Interestingly, treatment appeared to be of benefit also to formally
non-responding patients, since in this group the BVAS decreased
significantly (p=0.009) bymonth 6 although not reaching the primary
endpoint of N50% abatement.
No single demographic, clinical or laboratory variable at baseline
affected the outcome of therapy. However, the baseline BVAS tended
to be lower in non-responders than in responders (11.2 ± 3.8 vs
14.2 ± 6.6; p = 0.2).
Overall, 41 of 48 evaluable patients (85%) achieved a clinical
response throughout the study. The median time to remission/
improvement of vasculitis was one month (range 1–4 months). Seven-
teen of 41 responders (41%) experienced a relapse of vasculitis during a
1-year FU, with a median time of 6 months (range 4–12 months)
(Fig. 1). Eleven of 45 (24%) evaluable patients relapsed before month
6, and 6 of 41 patients relapsed between month 6 and month 12.
None of the variables tested by univariate analyses (sex, age, disease
duration, specific vasculitis manifestations, BVAS value, cryocrit, HCVTable 2
Comparison of the efficacy and safety of low-dose (present study) and high-dose (studies from
Variable Low-dosea High-do
Clinical responseb
Patients evaluable 48 208
Complete response 24 (50%)
Partial response 15 (31%)
Total response 39 (81%) 178 (86%
Laboratory response
Patients evaluable 48 202
Complete response 21 (44%) 83 (41%
Partial response 5 (10%) 43 (21%
Total response 26 (54%) 126 (62%
Relapse rate (mo 12)
Patients evaluable 41 84
Relapsers 17 (41%) 27 (32%
Median TTR (range)b 6 (4–12) 7 (4–12)
Adverse events
Patients evaluable 52 371
Total adverse events 6 (11.5%) 74 (19.9
Severe adverse events 1 (1.9%) 22 (5.9%
a Data refer to thenumber of patients (percentages), unless otherwise denoted. Data inhigh-d
Fisher's exact test. SD: standard deviation; TTR: time to relapse.
b Comparisons of complete and partial clinical responses are not shown because data wereviremia, B-cell count or occurrence of adverse events) was significantly
associated with an increased risk of relapse.
3.2.2. Laboratory efficacy
Complete laboratory response was defined as the complete
disappearance of cryoglobulins in the serum and a partial response as
a reduction of cryocrit to less than 50% of the baseline. A laboratory
response was achieved in 54% of patients throughout the study,
with a complete response in 44% (21/48) and a partial response in
10% (5/48) (Table 2). Decline of cryocrit after rituximab was quite
slow, as also reported previously [14]. In fact, at month 3 post-therapy
only 27% of patients had cleared cryoglobulins and 19% had N50% reduc-
tion. Eight of 26 laboratory responders had relapsed (any increase of
cryocrit) by month 12; five of these patients also presented a clinical
relapse.
Onemonth after the second infusion of rituximab all patients, except
one who did not receive full treatment because of a severe adverse
event during the first infusion, showed a complete B-cell depletion in
peripheral blood. B-cells repopulated (N5 B-cells/μl) in 33% (16/48) of
patients at month 3, and in 69% of evaluable patients at month 6;
at month 12 only one patient, a complete clinical responder, was still














ose patientswere obtained from the indicated references. The p-valueswere calculated by
inadequately reported in several literature studies.
Table 3
Adverse events in 52 patients treated with low-dose rituximab.





Serum sickness syndrome 2a
Flu-like syndrome 1
Late-onset neutropenia 1
Thrombophlebitis of the leg 1
Infectious 1
Legionellosis 1a
a One patient had serum sickness and legionellosis in two separate episodes.
893M. Visentini et al. / Autoimmunity Reviews 14 (2015) 889–896orwith cryocrit levelwas found. By contrast, a significant correlation be-
tween baseline cryocrit level and BVAS at any time-point (p = 0.003),
and between cryocrit level and decrease in BVAS over one-year
follow-up was observed (p = 0.031).3.3. Safety of low-dose rituximab
A total of 7 adverse events certainly or possibly related to treatment
were recorded in 6 patients (Table 3). An 80-y old female experienced
severe anaphylaxis (itching, skin rash, bronchospasm, wheezing)
immediately after starting her first infusion of rituximab; symptoms
resolved after interruption of infusion and administration of antihista-
mine and steroids. This patient was not treated further with rituximab.
Six mild/moderate adverse events occurred in five patients and were
considered possibly caused by rituximab. Two patients presented with
serum sickness (urticaria and fever) about one week after the second
infusion of rituximab; symptoms healed spontaneously in one case
andafter antihistamines and steroids in theother. Onepatient presented
3 months after rituximab with neutropenia (340 cells/μl), which
resolved spontaneously in 2 weeks. One patient had at month 1 throm-
bophlebitis of the left leg, which resolved after nonsteroidal anti-
inflammatory drugs and low-molecular-weight heparin. One patient
presented one week after the second rituximab infusion with a flu-like
syndrome, consisting of severe arthralgia, nausea and vomiting. Finally,
one patient, who also had developed serum sickness in a separateTable 4
Baseline characteristics of patients treated with high-dose rituximab for mixed cryoglobulinem
Author [Ref.] N of patients Age mean Rituximab dosage
1000 mg × 2 375 mg/m2 × 4 37
Cabibbo [24] 2 65 2
Cavallo [21] 13 65 13
Cervetti [16] 4 na 4
De Vita [18] 28 na 21 7
De Vita [29]a 28 63 28
De Vita [29]a 23 na 23
Ferri [27] 87 62 18 59 10
Gragnani [28] 21 65 21
Petrarca [19] 2 62 2
Petrarca [25] 19 63 19
Quartuccio [17] 5 57 5
Quartuccio [26] 5 57 5
Roccatello [15] 6 64 6
Saadoun [20] 21 53 21
Sansonno [14] 20 58 20
Senè [22] 22 57 4 18
Sneller [30] 12 53 12
Stasi [31] 14 60 14
Terrier [23] 12 57 12
Zaja [13] 15 64 15
Total (%) 359 87 236 36
a In this randomized study, patients treated with rituximab as first line therapy and control
separate groups. Blank cases denote no patients. na, not available.adverse episode, had Legionella pneumonia that healed upon antibiotic
therapy.
Six deaths unrelated to adverse events occurred throughout
the study. Three patients were responders: a 68-y old female died at
month 6 of acute pulmonary oedema due to kidney and heart failure,
and a 66-y old female at month 9 of heart failure. The third patient in
this group, a 56-y old male, died at month 12 of pulmonary atypical
mycobacterial infection and decompensated cirrhosis. The relation
mycobacterial infection with rituximab therapy was considered unlike-
ly, although two cases of severe infection by atypical mycobacteria have
been described after combined treatment with rituximab and immuno-
suppressive drugs [46]. Two non-responders died at months 3 and 7 of
complications of cryoglobulinemia, namely abdominal vasculitis and
kidney and heart failure. One patient died of myocardial infarction at
month 2, and her response could not be evaluated.
Finally, no significant changes of HCV viral load or of liver function
parameters were observed after low-dose rituximab.
3.4. Comparison of efficacy and safety of low-dose vs high dose rituximab
Nineteen articles [13–31] out of 297 reports on high-dose (i.e., higher
than 250 mg/m2 × 2) rituximab therapy for mixed cryoglobulinemia
screened in a systematic review of the literature were selected for
comparative purposes. Two studies were randomized controlled trials
[29,30], whereas all the others were uncontrolled studies including at
least 2 patients. Collectively, these studies provided fruitful information
in 359 patients, 26 of whom (7%) had a diagnosis of NHL. These 359
patients were treated with rituximab with either of the following
dosages: 1000 mg × 2 (87 patients), 375 mg/m2 × 4 (236 patients), or
375 mg/m2 × 6 (36 patients) (Table 4).
The selected studieswere very heterogeneous as to themethods and
timing of efficacy assessment and to the scoring system, and validated
BVAS was adopted only by the two randomized controlled trials [29,
30]. The time of efficacy assessment was, in most studies, at months 3
and 6, and the follow-up ranged between 6 and 31 months. For com-
paring the results of these studies with our data, we either calculated
the BVAS in trials in which adequate data were provided [13,15,17,19,
28,24], or adopted the definition of response used by the authors.
Table 2 summarizes a comparison of the efficacy and safety profiles
of low- and high-dose rituximab for MC. Low-dose rituximab yieldedia; data selected from a systematic review of the literature.
Purpura Ulcers Neuropathy Kidney disease Arthralgia




19 8 13 8 6
5 16 7
2 13 8
51 24 69 38
19 3 19 5 18
2 1 2 2 2
17 3 18 5 15
4 2 5 1
4 1 5 2
4 1 5 6 6
17 3 12 9 13
16 7 11 1 20
17 19 10
12 4 9 4 7
11 1 7 2 13
8 6 4 6
12 5 7 2 4
219 68 248 116 117
patients treated with rituximab after failure of conventional treatment were analyzed as
894 M. Visentini et al. / Autoimmunity Reviews 14 (2015) 889–896an overall (complete plus partial) clinical response of vasculitis 81%, a
figure not significantly different from the 86% that we calculated from
data reported in high-dose studies. The laboratory response rates
were also similar in low- and high-dose studies. Supplementary Fig. 2
provides detailed information on the clinical and laboratory response
rates and confidence intervals in the high-dose studies from which the
cumulative data were retrieved.
Fig. 2 illustrates the responses of single vasculitis manifestations in
our study and in those studies on high-dose rituximab in which these
data were detailed [13–19,21,24–30]. The response rates of skin ulcers,
kidney disease and arthralgia were very similar in low- and high-dose
trials; purpura responded somewhat worse (35/45, 77%, vs 178/210,
85%) and peripheral neuropathy somewhat better (40/45, 91%, vs
187/250, 75%) in our low-dose compared to high-dose studies, but
these differences were not statistically significant.
The proportion of patients who relapsed after clinical response
was 41% in our study and 32% in studies with high dose rituximab, a
difference not statistically significant (Table 2). Six studies [13,14,17,
24,29,30] provided data from 84 patients detailed enough for construct-
ing a Kaplan–Meier curve (Fig. 1). The median time to relapse was
7 months (range 4–12), whereas in our study the median time was 6
(range 4–12), a difference not statistically significant (p = 0.67).
Finally, the rate of adverse events could be compared in 371 patients
from studies using high-dose rituximab [13–15,17–19,21–27,29,30]
and in the 52 patients from our trial (Table 2). Studies with high-dose
rituximab displayed a trend to an increased frequency of adverse events
(19.9% vs 11.5% in our study), although this difference failed to reach
statistical significance (Table 2).
4. Discussion
After more than 15 years of experience with rituximab for the
treatment of a number of immunological disorders, drug dosages and
therapeutic schemes in different disease contexts are still empirical,
and dose/benefit studies are relatively scarce [41,47–51]. A large
number of studies demonstrated that rituximab is highly efficacious
and safe for the treatment of HCV-associated MC. Drug dosages most
commonly used were 375 mg/m2 given 4 times, as for the treatment
of B-cell neoplasia, and the so-called “rheumatoid arthritis protocol” of
1000 mg given twice.
In this study, we conducted a phase 2 single-arm, two-stage trial to
address the issue of whether a dosage of rituximab lower than those
commonly used may be equally effective in MC. Obviously, a trial ofFig. 2. Response of single vasculitis manifestations to low-dose (gray columns) or high-
dose (open columns) rituximab. Data illustrate the percentage of responders and the
number of evaluable patients for each vasculitis manifestation.equivalence or non-inferiority would be optimal for this purpose but,
based on the literature data and on our preliminary results [43], it
would demand the enrolment of such a large number of patients to
make it unfeasible in a rare disorder such as MC. Thus, we choose a
single-arm design with a 52-patients size and a 0.85 statistical power.
We performed a systematic review of the literature collecting all
available data from studies using rituximab at standard dosages for
MC treatment for a comparison with our results. The availability of
only two randomized controlled trials precluded, however, a meta-
analysis.
Concerning the comparison of the response rates in our study and in
literature reports, it is important to note that previous studieswere very
heterogeneous, particularly as to method and timing of efficacy assess-
ment and to the use of a validated scoring system, such as the BVAS,
which was exploited only by two randomized controlled trials [29,30].
Thus, for studies reporting patients' data at different time-points in
sufficient detail we could calculate a BVAS for a direct comparison
with the present study, whereas for the other studies we adopted the
definition of response provided by the authors. While dutifully taking
into account these limitations, low dose rituximab appeared to yield a
clinical response rate of 81%, a figure not significantly different from
the overall 86% response rate obtained with higher dosages. The analy-
sis of the response of single organ manifestations may be less biased by
different methods of assessment; thus, also by this approach the
response of vasculitis appeared to be very similar using low-dose or
high-dose rituximab.
Among the 19 selected studies on high-dose rituximab for MC, six
[13,14,17,24,29,30] provided detailed data useful for comparing the
12-month relapse rate and the time-to-relapse. The relapse rate was
somewhat higher, and the time-to-relapse was somewhat shorter in
patients treated with low-dose rather than high-dose rituximab (41%
and 6 months vs 32% and 7 months, respectively); however, these dif-
ferences did not reach statistical significance. In an extended phase of
our trial, six relapsers received a second course of low-dose rituximab,
which led to sustained remission in all except one. Thus, even if
assuming as real a 20% higher relapse rate using low-dose rituximab,
retreatment of relapsers with the same dosage would remain cost-
effective compared to treatment and retreatment with high-dose
regimens [29,30].
Concerning laboratory response, we had a similar complete re-
sponse rate (disappearance of cryoglobulins) compared to high-dose
studies, whereas partial responses (N50% decrease of cryocrit) were
somewhat inferior. The latter difference could be related in part to the
less stringent definition of partial response in some studies [13,16],
and to remarkably lower baseline cryocrit levels reported in other
studies [25].
Adverse events tended to be less frequent in our trial than in high-
dose studies, although the difference failed to reach statistical signifi-
cance. Sène et al. [22] reported a high rate of severe adverse events
after high-dose treatment of patients with high cryocrit values, and
suggested a dose-dependency of rituximab side effects in these patients.
Thus, more data are needed to confirm that low-dose rituximab might
be safer in patients with mixed cryoglobulinemia.
We recorded six deaths (11.5%) throughout the study, none ofwhich
was related to rituximab treatment. Previous studies with high-dose
rituximab reported similar high rates of treatment-unrelated deaths of
10.5% [29], 9% [23] and 13% [52], mostly associated, as in the case of
our study, with older age and comorbidities.
Our phase 2 study provides evidence that rituximab treatment for
mixed cryoglobulinemia at the reduced dosage of 250 mg/m2 × 2 has
similar effectiveness than at higher dosages. These results may help to
optimize rituximab therapy for patients with HCV-associated mixed
cryoglobulinemia who fail to respond to antiviral therapy [9]. The
recently available DAA agents promise to dramatically reduce the pro-
portion of patients who need salvage therapy with rituximab [10–12].
However, low-dose rituximab in combination with DAA is likely to be
895M. Visentini et al. / Autoimmunity Reviews 14 (2015) 889–896of value for treating severe forms of cryoglobulinemic vasculitis [23,53],
and may provide a cost/effective and possibly safer strategy for treating
the 10–30% of mixed cryoglobulinemia cases that are not associated
with HCV infection [52].
Take-home messages
• Rituximab at the low dosage of 250 mg/m2 × 2 is as effective as the
higher dosage of 375 mg/m2 × 4 for treating HCV-associated mixed
cryoglobulinemia
• The low-dose regimen may improve the cost/benefit profile of rituxi-
mab therapy for mixed cryoglobulinemia.Disclosures
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